Nachrichten zur Catalyst Pharmaceuticals Inc. Aktie

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

Angelini Pharma has entered into a definitive agreement to acquire Catalyst Pharmaceuticals.…

Catalyst Pharmaceuticals stock surges on takeover report

Catalyst Pharmaceuticals stock surges on takeover report…

Italy’s Angelini Said to Explore Catalyst Pharma Acquisition

Italian drugmaker Angelini Pharma is exploring a potential acquisition of Catalyst Pharmaceuticals Inc. as it looks at deals to expand…

Catalyst Pharmaceuticals: Favorable Trial Outcome Could Be A Meaningful Overhang

…

Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y

CPRX Q3 earnings and revenues beat estimates, driven by strong Firdapse and Agamree sales, while raising the full-year 2025 total…

Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program

CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a…

Earnings call transcript: Catalyst Pharmaceuticals Q2 2025 beats EPS forecast By Investing.com

Earnings call transcript: Catalyst Pharmaceuticals Q2 2025 beats EPS forecast…

Catalyst Pharmaceuticals, Inc. (CPRX) Hits Fresh High: Is There Still Room to Run?

Catalyst (CPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a…

Catalyst Pharmaceuticals stock soars to all-time high of $26.49 By Investing.com

Catalyst Pharmaceuticals stock soars to all-time high of $26.49…

Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y

CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.…

Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Markets Swoon on Thursday

As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the…

Catalyst Pharmaceuticals: Wachstumsstarker Spezialist für seltene Krankheiten

Erfolgreich mit Orphan Drugs: Catalyst punktet mit margenstarken Nischenprodukten wie FIRDAPSE und dem Wachstumstreiber AGAMREE. Starkes Quartal, zögernder Konsens:…

Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts

…

Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference

CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a…

Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE

…

Catalyst Pharmaceuticals: Agamree Is Its Key To A Sustainable Future

…

Catalyst Pharmaceuticals executive sells shares worth $272,654 By Investing.com

Catalyst Pharmaceuticals executive sells shares worth $272,654…

Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work

CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a…

Zacks.com featured highlights include Barrick Gold, Catalyst Pharmaceuticals, Allegiant Travel and America Movil

Barrick Gold, Catalyst Pharmaceuticals, Allegiant Travel and America Movil are part of the Zacks Screen of the Week article.…

Catalyst Pharmaceuticals: High Valuation Amid Weak Long-Term Prospects (Rating Downgrade)

…

Catalyst Pharmaceuticals: New Products In Proving Phase

…

Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®

CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage…

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

…

GNW-Adhoc: Santheras Partner Catalyst Pharmaceuticals lanciert AGAMREE® (Vamorolon) in den Vereinigten Staaten

^* AGAMREE® ist von der U.S. FDA zugelassen und jetzt in den USA für die Behandlung von…

GNW-Adhoc: Santheras Partner Catalyst Pharmaceuticals lanciert AGAMREE® (Vamorolon) in den Vereinigten Staaten

^* AGAMREE® ist von der U.S. FDA zugelassen und jetzt in den USA für dieBehandlung von Duchenne-Muskeldystrophie (DMD) bei Patienten…

Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States

Pratteln, Switzerland, March 14, 2024 – Santhera Pharmaceuticals (SIX: SANN) is pleased to note the launch of AGAMREE® (vamorolone) for the…

Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference

CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage…

dpa-AFX ProFeed